AUG 11, 2026 · PHASE 3 TRIAL
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
ClinicalTrials.gov
This is a Phase 3 registry record with no reported results; the study is actively recruiting and outcome data are not yet posted.
Reported
Planned sample size426
Primary outcome measureChange from baseline on Cohen-Mansfield Agi…
Study phasePHASE 3